Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — splitting or halving a 5mg Mounjaro dose is not recommended and goes against the licensed way the medicine works. Each KwikPen is a sealed, pre-set device; there is no mechanism to extract and administer half its contents safely or accurately. If 5mg is causing side effects, the right step is a conversation with your prescriber, not a modified dose. These are prescription-only medicines that require clinical oversight at every stage.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is a question our prescribers hear most weeks, and it nearly always comes from the right place, someone feeling nauseous or uncomfortable after moving up to 5mg, who just wants to find a way to stay in the programme without feeling rough. That instinct is understandable. But the premise doesn't hold up technically.
A Mounjaro KwikPen is a sealed, factory-set device. Each pen delivers four identical weekly injections at its labelled strength. There is no adjustable dial, no syringe to draw from, no way for a patient at home to extract a partial dose and be confident they have received a consistent, sterile amount. Attempting to modify the pen, aspirate from it with another device, or inject only 'some' of its contents introduces the risk of inaccurate dosing and potential contamination, neither of which your prescriber would sanction. The general picture on halving any Mounjaro dose is the same regardless of which strength is involved.
The NHS patient information for tirzepatide is clear on this: the pen is used as supplied, following the instructions in the Patient Information Leaflet, under prescriber guidance. If the current dose is not tolerable, that is clinical information, it should go back to the prescriber, not be managed by modifying the device.
Mounjaro's licensed schedule begins at 2.5mg. That first pen exists entirely to let your digestive system adjust to the medicine, it is a tolerability step, not a therapeutic target. The full Mounjaro dose schedule then steps through 5mg, 7.5mg, 10mg, 12.5mg and 15mg, with increases typically made in four-week intervals by the prescriber.
Five milligrams is the first true step-up. Some people sail through it; others notice more nausea, reflux or fatigue than they did at 2.5mg. That is entirely normal. The GI effects of GLP-1 and GIP receptor agonists tend to be most noticeable when a dose increases, and they usually ease within one to two weeks as the body settles. Practical guidance on taking 5mg covers things like timing, hydration and meal size that can genuinely reduce discomfort, adjustments worth trying before drawing conclusions about the dose itself.
Prescribers can also hold a patient at any dose for longer than four weeks if the clinical picture warrants it. That flexibility is built into the programme. Cutting a dose in half outside any clinical instruction is not the same thing, it bypasses the structured plan and makes it harder for the prescriber to understand how you are actually responding. More on the 5mg pen specifically explains what to expect from this stage of treatment.
If side effects at 5mg are the reason for the question, there are several legitimate routes. Your prescriber can extend your time at 5mg, give specific dietary guidance, or in some cases return you temporarily to 2.5mg, all based on a real clinical assessment of your situation. None of those options require you to interfere with the pen.
For context, the most common side effects reported with tirzepatide are gastrointestinal: nausea, loose stools, reflux, and occasionally vomiting. They peak around dose increases and tend to settle. Eating smaller, lower-fat meals, staying well hydrated and avoiding lying down immediately after eating can all make the adjustment period shorter. Guidance on what to do around your next dose covers practical steps in more detail.
The broader picture on NICE's recommendation for tirzepatide (including NICE technology appraisal TA1026) reflects thousands of study participants who followed the licensed titration pathway. The weight outcomes reported in clinical trials (around 20–21% average body-weight reduction at 15mg in SURMOUNT-1) were achieved through the structured schedule, not through modified dosing. Departing from that structure without clinical input means departing from the evidence base the prescriber is working from.
If cost is somewhere behind this question (whether a lower dose might stretch a pen further) our guide to Mounjaro costs in the UK addresses that honestly, including what legitimate private treatment actually includes. It is worth reading before drawing conclusions based on price alone.
Contact whoever prescribed your Mounjaro. That is the entire answer. If you are a patient with a GPhC-registered online pharmacy, reach out through their aftercare channel, at nume, that means our clinical team is available seven days a week to advise you. A prescriber can review your notes, ask the right questions and make a clinical decision about your dose. That might mean staying at 5mg a little longer, adjusting what you eat around injection day, or, in some cases, pausing the titration altogether.
What it should not mean is using a device in a way it was not designed for. Broader discussion of half-dosing approaches also concludes this way: the pen's design forecloses the option, and the clinical process offers a better one. The NHS guidance on tirzepatide is also worth a read if you want to understand the medicine in plain terms before your next prescriber conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.